UKG Named Leader in HCM for 14th Consecutive Year
UKG, a leading provider of HR, payroll, workforce management, and culture solutions, today announced that the company has ...
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.